Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Feb 16, 2022 12:42pm
94 Views
Post# 34434280

RE:RE:RE:RE:RE:Trog IV push data

RE:RE:RE:RE:RE:Trog IV push dataThe issue is and has been they make no efforts to reach out to broader audience. It's like one run a business and the marketing efforts  keep targeting the exciting clients the very best outcome is retaining those customers. If you want to expand you need to go after new clients simple logics. These PRs, their social media posts, YouTube clips etc won't create any demand because most likely only their exciting investors see them. So they put a post on LinkedIn and it gets 10 likes by people working for the company and then the next post and... If you want to grow your audience you need to increase your presence using all the tools available. To me it seems this business is run by someone who is approaching their retirement now!!!    
Wino115 wrote: I think if there is a market view that TH1902 is powerful and safe, with a better than average chance given the "bomb" is just plain old taxol, they'll use any pop to trigger a bit of the ATM or all of it.  It will accomplish 3 positive things -- give them enough to see through the 1b (maybe even expand it), get the institutions they have said want to invest but the markets too illiquid and volatile (the old spigot problem IDed 2 yeras ago), and get Cantor on board to at least cover it and amplify the science and company to new shareholders.

If they were smart about it, they wouldn't give the insitutions they've talked with 100% of what they want so that there is some ongoing demand in the market and they can use them to increase the volume and price in the market. Let more go higher if need be and feed the demand, don't squelch it. I would hope we're significantly higher though.

Then you have enough time to see the 1b through and Phase 2 design and do the proper $150mil come winter or beyond for Phase 2, NASH start, convert covered (if it's not above convert price).  Simple, solid strategy get's you all you need. Future you can partner rights or programs for whatever cash you need.  We just need to see that one thing it depends on --TH1902 POC in humans.



SPCEO1 wrote: It seems to me that there is very likely to be an offering on the near term horizon. I am assuming this will happen and all of us should be assuming that. The big question is will this offering be the polar opposite of the last one. That would certainly be nice if it happens as it would help redeem the ONO to some extent if they were able to get an offering off at a nice price with good analyst coverage following and follow on buying from the insitutions that participated in the offering (which TH did at least get some of that with the ONO). Also, will they raise an appropriate amount of money or will we think they raised too much? 

I am personally in favor of an offering that works on all levels. We cannot know how necessary the offering will be or how large it should be until we see the phase 1a data and hear TH's strategy for exploiting whatever they have. But I am hopeful that whatever offering comes down in the next few months will be something we can be happy about.

SABBOBCAT wrote: Sniff, sniff ... I smell a financing... TH only breaks silence this frequently when they need money

 




<< Previous
Bullboard Posts
Next >>